An emerging new type of oral cancer in men has increased over the last 15 years. The culprit is human papillomavirus (HPV), and key social factors are contributing to its growth. April is Oral Cancer Awareness Month, and with the ongoing rise in cases of throat cancer linked to HPV, many medical and dental professionals are encouraging the public to take measures in an effort to help prevent this form of cancer.
You are here
Human papillomavirus (HPV) is widely known to cause nearly all cases of cervical cancer. However, you might not know that HPV also causes 70 percent of oropharyngeal cancer, a subset of head and neck cancers that affect the mouth, tongue, and tonsils. Although vaccines that protect against HPV infection are now available, they are not yet widespread, especially in men, nor do they address the large number of currently infected cancer patients.
A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology.
A new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked head and neck cancer patients to ensure they remain cancer-free after treatment.
A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
The Case Western Reserve-led research team will analyze computerized images of tissue samples for patterns which could become "biomarkers," or predictors, for determining relative risk for recurrence in one particularly common type of head and neck cancers.
Those tumors, known as oropharyngeal cancers, occur primarily at the base of the tongue and in the tonsils.
Join in Spreading HPV Awareness to Improve Women’s Health Through Education Across the Globe
The Global Initiative Against HPV and Cervical Cancer (GIAHC) that is leading the way in education, empowerment and eradication of Human Papillomavirus(HPV) and cervical cancer announces a partnership with the International Papillomavirus Society (IPVS) for HPV Awareness Day, March 4, 2018.
Tobacco and alcohol use may be the most common cause of head and neck cancers, but a new culprit has come on the scene in recent years.
The human papillomavirus (HPV) is now responsible for more than 60 percent of cases of oropharyngeal cancer diagnosed at Penn State Milton S. Hershey Medical Center, according to Dr. David Goldenberg, professor of surgery and medicine and director of Head and Neck Surgery.
Oropharyngeal cancer can affect the back third of the tongue, the soft palate, side and back walls of the throat and the tonsils.
When it comes to cancer-causing viruses like human papillomavirus, or HPV, researchers are continuing to find that infection with one strain may be better than another.
In an analysis of survival data for patients with a particular type of head and neck cancer, researchers from the University of North Carolina Lineberger Comprehensive Cancer Center confirmed findings that a particular strain of HPV, a virus linked to a number of cancers, resulted in better overall survival for patients with oropharyngeal cancer than patients with other strains of the virus in their tumors.
Cancer of the oropharynx has become increasingly common: In the United States alone, the number of newly diagnosed cases has tripled over the past three decades. About 70 percent of these tumors are caused by infection with human papillomavirus (HPV) type 16.